FINANCIAL INFORMATION

Deferred revenue, current portion

The Company’s current deferred revenue balance was US$14.0 million and US$12.2 million as
of March 31, 2018 and December 31, 2017, respectively, and represents the amount of upfront fees
from the Celgene collaboration agreement
that were allocated to the research and development
services to be provided by the Company under the collaboration, that are expected to be performed
over the next twelve months. The Company had no current deferred revenue as of December 31, 2016

Tax payable

The Company’s taxes payable balances of US$9.9 million as of March 31, 2018 and US$9.2
million and US$0.8 million as of December 31, 2017 and 2016, respectively, represent corporate cash
income taxes owed to authorities in the U.S. and China.

Key Financial Ratios

The following table sets forth our key financial ratios for the periods indicated:

As of March 31,

As of December 31,

2018

2017

2016

Gross margin — products (1).....................................
Current ratio (2) ........................................................
Gearing ratio (3)........................................................

80.4%
11.2
12.8%

79.6%
6.2
24.2%

—
10.7
4.9%

Notes:
(1)
(2)
(3)

Gross margin on our products equals gross profit divided by revenue for the period. In 2016, we had no product sales.
Current ratio equals current assets divided by current liabilities as of the end of the period.
Gearing ratio equals total interest-bearing loans divided by total equity as of the end of the period.

See the paragraphs headed “— Results of Operations — Comparison of the Three Months Ended
March 31, 2018 and 2017” and “— Comparison of the Years Ended December 31, 2017 and 2016” in
this section for a discussion of the factors affecting our results of operations during the respective
periods.

Liquidity and Capital Resources

Since inception, we have incurred annual net losses from our operations. Substantially all of our
losses have resulted from the funding of our research and development programs and selling, general
and administrative expenses associated with our operations. We incurred net losses of US$105.1
million and US$50.6 million for the three months ended March 31, 2018 and 2017, respectively, and
US$95.9 million and US$119.2 million for the years ended December 31, 2017 and 2016, respectively.
As of March 31, 2018 and December 31, 2017, we had an accumulated deficit of US$438.0 million
and US$333.4 million, respectively. Our operating activities used US$104.5 million and US$35.7
million for the three months ended March 31, 2018 and 2017 and provided US$12.8 million for the

— 284 —

